Current Landscape of Personalized Therapy
| Autor: | Amanda S. Cass, Leora Horn |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Disease Systemic therapy B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Anaplastic lymphoma kinase Medicine Humans Epidermal growth factor receptor Molecular Targeted Therapy Precision Medicine Lung cancer Chemotherapy biology business.industry Immunotherapy medicine.disease 030228 respiratory system Pharmacogenetics 030220 oncology & carcinogenesis Toxicity biology.protein Surgery business |
| Zdroj: | Thoracic surgery clinics. 30(2) |
| ISSN: | 1558-5069 |
| Popis: | Almost a half of patients diagnosed with nonesmall-cell lung cancer (NSCLC) present with incurable disease, and a significant number of patients who are treated with curative intent for early-stage disease will eventually recur. Systemic therapy is selected based on tumor histology, squamous versus nonsquamous NSCLC, molecular testing, and PD-L1 score. Depending on PD-L1 score, patients are eligible for immunotherapy alone or in combination with chemotherapy in the first-line setting. Oncogenic driver mutations can be detected in approximately 50% of patients with nonsquamous NSCLC of which several can be targeted therapeutically with small molecular inhibitors. Continued research is needed for more specific agents with less toxicity and better central nervous system penetration, and agents to treat patients who develop resistance against targeted treatments and immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|